Target Name: GZMK
NCBI ID: G3003
Review Report on GZMK Target / Biomarker Content of Review Report on GZMK Target / Biomarker
GZMK
Other Name(s): granzyme 3 | Tryptase II | tryptase II | NK-TRYP-2 | Granzyme K | GRAK_HUMAN | granzyme K (granzyme 3; tryptase II) | NK-Tryp-2 | NK-tryptase-2 | TRYP2 | fragmentin-3 | granzyme K | Granzyme-3 | Fragmentin-3 | Granzyme K (serine protease, granzyme 3; tryptase II) | granzyme K (serine protease, granzyme 3; tryptase II)

GZMK: A Potential Drug Target and Biomarker

G protein-coupled receptors (GPCRs) are a family of transmembrane proteins that play a crucial role in cellular signaling. GPCRs are involved in various physiological processes, including sensory perception, neurotransmission, and hormone signaling. GZMK is a GPCR that has been identified as a potential drug target and biomarker.

The GZMK receptor is a member of the GPCR family and is located on the surface of certain cells, including neurons and endothelial cells. GZMK is involved in the regulation of neurotransmitter release and cell signaling. The GZMK receptor has been shown to play a role in the regulation of pain perception, anxiety, and depression.

GZMK is a highly selective GPCR, which means that it is only able to interact with certain types of molecules. The GZMK receptor is known to interact with GABA, a neurotransmitter that plays a role in the regulation of pain perception and anxiety. GZMK is also known to interact with serotonin, another neurotransmitter that is involved in mood regulation.

GZMK has been shown to play a role in the regulation of pain perception. Studies have shown that GZMK is involved in the regulation of pain sensitivity and that it is a potential drug target for the treatment of pain. GZMK is also known to interact with opioids, which are drugs that are used to treat pain. This suggests that GZMK may be a good candidate for the treatment of chronic pain conditions such as cancer-induced pain.

In addition to its potential role in pain perception, GZMK is also known to be involved in the regulation of anxiety and depression. Studies have shown that GZMK is involved in the regulation of anxiety-like behavior and that it is a potential drug target for the treatment of anxiety and depression. GZMK is also known to interact with dopamine, a neurotransmitter that is involved in the regulation of mood and emotion. This suggests that GZMK may be a good candidate for the treatment of symptoms of anxiety and depression.

GZMK is also a potential biomarker for the diagnosis of neurodegenerative diseases. Neurodegenerative diseases are a group of conditions that are characterized by the progressive loss of brain cells and the development of neuropathological changes. GZMK is involved in the regulation of neurotransmission and is thought to be involved in the pathophysiology of neurodegenerative diseases. This suggests that GZMK may be a valuable tool for the diagnosis and treatment of neurodegenerative diseases.

GZMK is also a potential drug target for the treatment of psychiatric disorders. psychiatric disorders are a group of conditions that are characterized by the presence of symptoms such as depression, anxiety, and psychosis. GZMK is involved in the regulation of neurotransmission and is thought to be involved in the pathophysiology of psychiatric disorders. This suggests that GZMK may be a good candidate for the treatment of symptoms of psychiatric disorders.

In conclusion, GZMK is a GPCR that has been shown to play a role in the regulation of pain perception, anxiety, and depression. GZMK is also a highly selective GPCR that interacts with GABA and serotonin. These properties make GZMK a potential drug target and biomarker for the treatment of a variety of conditions, including chronic

Protein Name: Granzyme K

The "GZMK Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GZMK comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

GZMM | H1-0 | H1-1 | H1-10 | H1-10-AS1 | H1-2 | H1-3 | H1-4 | H1-5 | H1-6 | H1-7 | H1-8 | H1-9P | H19 | H19-ICR | H2AB1 | H2AB2 | H2AB3 | H2AC1 | H2AC11 | H2AC12 | H2AC13 | H2AC14 | H2AC15 | H2AC16 | H2AC17 | H2AC18 | H2AC20 | H2AC21 | H2AC25 | H2AC3P | H2AC4 | H2AC6 | H2AC7 | H2AJ | H2AP | H2AX | H2AZ1 | H2AZ1-DT | H2AZ2 | H2AZ2-DT | H2AZP2 | H2BC1 | H2BC10 | H2BC11 | H2BC12 | H2BC12L | H2BC13 | H2BC14 | H2BC15 | H2BC17 | H2BC18 | H2BC20P | H2BC21 | H2BC26 | H2BC27P | H2BC3 | H2BC4 | H2BC5 | H2BC6 | H2BC7 | H2BC8 | H2BC9 | H2BP1 | H2BP2 | H2BP3 | H2BW1 | H2BW2 | H2BW4P | H3-3A | H3-3B | H3-4 | H3-5 | H3-7 | H3C1 | H3C10 | H3C11 | H3C12 | H3C13 | H3C14 | H3C15 | H3C2 | H3C3 | H3C4 | H3C6 | H3C7 | H3C8 | H3P16 | H3P36 | H3P37 | H3P44 | H3P5 | H3P6 | H4C1 | H4C11 | H4C12 | H4C13 | H4C14 | H4C15 | H4C16